Stuff

Question 1

Class I Rec

Answer 1

Conditions for which there is evidence and/or
general agreement that a given procedure or treatment
is beneficial, useful, and effective.

Question 2

Class II Rec

Answer 2

Conditions for which there is conflicting
evidence and/or divergence of opinion about the
usefulness/efficacy of a procedure or treatment.

Question 3

Class IIa

Answer 3

Weight of evidence/opinion is in favor of

usefulness/efficacy

Question 4

Class IIb

Answer 4

Usefulness/efficacy is less well established

by evidence/opinion.

Question 5

Class III Rec

Answer 5

Conditions for which there is evidence
and/or general agreement that a procedure/treatment
is not useful/effective and in some cases may be
harmful.

Question 6

Triangle of Koch

Answer 6

AV node location

Tendon of Todaro
Coronary sinus
Septal attachment of TV

Question 7

Septum prim

Answer 7

Forms roof of atrium

Question 8

Carney complex

Answer 8

• recurrent atrial myxomas
• hyperpigmentation of skin
• non cardiac benign tumors
• ACTH-independent hypercortisolism and other endocrine d/o
• positive family h/o these features

Question 9

LAD leads

Answer 9

V1-V6

Question 10

Cx leads

Answer 10

I, aVL, V5,V6

Question 11

RCA leads

Answer 11

II, III, aVF

Question 12

hit

Answer 12

2 types of heparin associated thrombocytopenia: non-immune (HIT Type 1) and immune heparin induced thrombocytopenia (HIT Type 2). HIT Type 1 is associated with mild thrombocytopenia within 2-3 days after starting heparin treatment. Platelet counts less than 100 K/mm3 are rare and the counts recover within days after discontinuation of heparin. HIT Type 2 is caused by antibodies to platelet factor 4 (PF4)/heparin complexes. Binding of the antibody can lead to platelet activation and to tissue factor expression, which is highly prothrombotic. The timeline of HIT Type 2 is broader (4-14 days) unless there has been previous heparin exposure, and thrombocytopenia is usually moderate to severe (commonly <100